Evaluating liver disease screening for individuals with alcohol use disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the effectiveness of screening for liver disease using liver stiffness measurement in individuals undergoing treatment for alcohol use disorder. Participants will be randomly assigned to either receive an invitation for liver stiffness measurement and blood sampling or just blood sampling as a control. The primary outcome will be measured by the level of abstinence or light alcohol consumption after six months. The study focuses on individuals without a prior history of liver disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Attending outpatient treatment for alcohol use disorder (international classification of disease version 10: F102: alcohol dependence or F101: harmful alcohol use) at Novavi Køge or Novavi Roskilde
* Informed written consent

Exclusion Criteria:

* Not speaking Danish or English
* Severe liver disease (known by the participant)

Where it's running

• Novavi Køge
  Køge, Denmark Recruiting
• Novavi Roskilde
  Roskilde, Denmark Recruiting

Study contacts

• Principal investigator: Gro Askgaard, PHD — Zealand University Hospital
• Study coordinator: Pernille Dahlin, MD
• Email: pedah@regionsjaelland.dk
• Phone: +45 30291114

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for adults with alcohol use disorder

  This study will test whether BrainsWay Deep TMS can reduce heavy drinking in adults with moderate to severe alcohol use disorder compared with a sham procedure.

  Recruiting at 9 sites Brainsway · Tuscaloosa, Alabama and 10 other locations · NCT07216872

• Functional connectivity–guided transcranial magnetic stimulation for alcohol use disorder

  This study will test whether a single fMRI-guided session of transcranial magnetic stimulation (TMS) can reduce alcohol-cue brain reactivity and help people with moderate-to-severe alcohol use disorder stay abstinent.

  Recruiting VA Palo Alto Health Care System · Palo Alto, California · NCT06415721

• Effects of comorbidity on people with severe mental illness

  This study tests how having both alcohol/substance use and a severe mental illness affects hospitalizations, medications, and social participation among adults followed at a mental health center.

  Recruiting Abant Izzet Baysal University · Bolu, Bolu · NCT07692984

• Transcutaneous auricular neurostimulation (tAN) for reducing alcohol withdrawal in people with alcohol use disorder

  This trial will try a five-day ear‑stimulation device (tAN) versus a sham device to reduce alcohol withdrawal symptoms in adults with moderate-to-severe alcohol use disorder.

  Recruiting Spark Biomedical, Inc. · Houston, Texas · NCT07281261

• Tirzepatide's effects on alcohol intake in patients with schizophrenia and alcohol use disorder

  This study is testing if the medication tirzepatide can help people with schizophrenia and alcohol use disorder drink less alcohol over six months.

  Recruiting at 2 sites Phase 2 Psychiatric Centre Rigshospitalet · Aalborg, Denmark and 1 other locations · NCT06939088

• Comparing two therapies for alcohol addiction

  This study is testing which therapy, Combined Behavioral Intervention or Ericksonian Hypnotherapy, works better to help adults with alcohol addiction reduce their drinking and improve their overall well-being.

  Recruiting Beykoz University · Istanbul · NCT06916754

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.